About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
Email Alert
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
Email Alert
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
Press Release
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2026-04-01
Enhancing Treatment for Breast Cancer: China’s First Subcutaneous Pertuzumab/Trastuzumab Combination HLX319 Approved for Clinical Trial
2026-03-31
Henlius' Next-Generation rHuPH20 Approved for Clinical Trials, Accelerating Subcutaneous Delivery Platform Development
2026-03-30
Henlius Receives Two Positive CHMP Opinions for Serplulimab, Advancing Global Regulatory Progress
2026-03-27
Latest Results from Studies of Henlius’Serplulimab in Lung Cancer Released at ELCC 2026
2026-03-26
First Patient Dosed in a Phase 1b/2 Clinical Trial of HLX701 Combination Therapy in Advanced Colorectal Cancer
2026-03-24
Health Canada Approves Henlius’ BILDYOS® (Denosumab Injection) and TUZEMTY® (Denosumab Injection), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
2026-03-20
NMPA Grants IND Approval for Henlius’ Nivolumab Biosimilar HLX18 Following U.S. FDA Clearance
2026-03-20
Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
2026-03-19
Henlius to Showcase Seven FIC/BIC Innovative Assets at AACR 2026, Highlighting Accelerated Early-Stage Innovation
1
2
3
4
